Skip to main content
. 2022 Dec 15;13:1042072. doi: 10.3389/fimmu.2022.1042072

Figure 2.

Figure 2

Correlation between HER2 amplification and TMB in patients with BRCA, LUAD and STAD. (A) Tissue TMB driven by HER2 amplification among three tumors from TCGA cohorts. (B) Tissue and blood TMB driven by HER2 amplification among three tumors from the validation set. TMB, tumor mutation burden, was defined as the total number of somatic nonsynonymous per megabyte. P < 0.05 was regarded as significantly different. ***P < 0.001, **P < 0.01, *P < 0.05.